In this issue:
Cobitolimod for moderate-to-severe, left-sided UC
Pretreatment MRE predicts TNF-α inhibitor response in CD
Ustekinumab for perianal CD
Disease activity and drug persistence with ustekinumab for CD
Combined biologic/immunomodulator decreases IBD complications
Outcomes after (modified) SSIS for extensive Crohn’s ileitis
Tofacitinib for real-world moderate-to-severe UC
Personalised adherence support for maintenance IBD treatments
Histological markers of clinical relapse in endoscopically quiescent UC
Antibiotic cocktail for paediatric acute severe colitis
Please login below to download this issue (PDF)